Mark T. Fleming - Publications, H-index & Citations

Mark T. Fleming

Virginia Oncology Associates

43H指数

213论文数

1.6W被引数

收录论文 40

发表时间

Developing a situational judgement test (SJT) for safety-minded leadership in high-hazard industries 开发针对高风险行业安全意识型领导力的情境判断测验（SJT）

Journal of Safety Research

IF4.4

2025-12-09

OAAI

Ryan Cook; Gregory G. Anderson; Mark Fleming

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer [177Lu]Lu-PSMA-617与雄激素受体途径抑制剂变化的PSMAfore 3期试验在未接受紫杉烷治疗的转移性去势抵抗性前列腺癌患者中的最终总生存期和安全性分析

Annals of Oncology

IF65.4

2025-07-17

OAAI

K. Fizazi; K.N. Chi; N.D. Shore; K. Herrmann; J.S. de Bono; D. Castellano; J.M. Piulats; A. Fléchon; X.X. Wei; H. Mahammedi; G. Roubaud; M. Fleming; T. Haas; S. Ghebremariam; T.N. Kreisl; S. Rajagopalan; O. Sartor; M.J. Morris

lancet oncology

IF0

2025-05-26

PREAI

Karim Fizazi; Michael J Morris; Neal D Shore; Kim N Chi; Michael Crosby; Johann S de Bono; Ken Herrmann; Guilhem Roubaud; James Nagarajah; Mark Fleming; Brian Lewis; Luke Nordquist; Natalie Carnahan; Samson Ghebremariam; Marianna Hertelendi; Daniel Castellano; Oliver Sartor

Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) plus tremelimumab (T) plus enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial VOLGA III期试验安全启动队列中，使用新辅助度伐利尤单抗（D）联合特瑞普利单抗（T）和恩沃利单抗（EV）治疗不适合顺铂的肌肉浸润性膀胱癌（MIBC）患者的循环肿瘤DNA（ctDNA）清除情况。

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Drakaki, A.; Powles, T. B.; Wang, Y.; Bupathi, M.; Joshi, M.; Fleming, M. T.; de Liano Lista, A. Gomez; Morales Barrera, R.; Pili, R.; Boulos, S.; Shrestha, Y.

Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore 症状性骨骼事件、健康相关生活质量及疼痛：[177Lu]Lu-PSMA-617在紫杉烷类药物初治的PSMA阳性转移性去势抵抗性前列腺癌患者中的III期研究——PSMAfore研究第三次中期分析

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Fizazi, K.; Morris, M. J.; Shore, N. D.; Chi, K. N.; Crosby, M.; de Bono, J. S.; Herrmann, K.; Roubaud, G.; Nagarajah, J.; Fleming, M. T.; Lewis, B.; Nordquist, L. T.; Castellano Gauna, D. E.; Carnahan, N.; Ghebremariam, S.; Hertelendi, M.; Sartor, O.

True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2024-05-23

OAAI

Fleming, Mark T.; Hermsen, Rick; Purysko, Andrei S.; Chau, Albert; Davis, Phillip; Chapin, Brian F.; Schuster, David M.

JOURNAL OF UROLOGY

IF6.8

2023-09-01

PREAI

Jani, Ashesh B.; Ravizzini, Gregory C.; Gartrell, Benjamin A.; Siegel, Barry A.; Twardowski, Przemyslaw; Saltzstein, Daniel; Fleming, Mark T.; Chau, Albert; Davis, Phillip; Chapin, Brian F.; Schuster, David M.

Reply by Authors

JOURNAL OF UROLOGY

IF6.8

2023-08-01

PREAI

Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)18F-rhPSMA-7.3正电子发射断层扫描在疑似前列腺癌复发男性中的诊断性能和安全性: 来自3期，前瞻性，多中心研究 (SPOTLIGHT) 的结果

JOURNAL OF UROLOGY

IF6.8

2023-08-01

OAAI

Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

EUROPEAN UROLOGY OPEN SCIENCE

IF4.5

2023-04-01

OAAI

Siefker-Radtke, Arlene O.; Necchi, Andrea; Park, Se Hoon; Garcia-Donas, Jesus; Huddart, Robert A.; Burgess, Earle F.; Fleming, Mark T.; Kalebasty, Arash Rezazadeh; Mellado, Begona; Varlamov, Sergei; Joshi, Monika; Duran, Ignacio; Tagawa, Scott T.; Zakharia, Yousef; Qi, Keqin; Akapame, Sydney; Triantos, Spyros; O'Hagan, Anne; Loriot, Yohann

Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial

FUTURE ONCOLOGY

IF2.6

2022-05-24

OAAI

Pal, Sumanta K.; Somford, Diederik M.; Grivas, Petros; Sridhar, Srikala S.; Gupta, Shilpa; Bellmunt, Joaquim; Sonpavde, Guru; Fleming, Mark T.; Lerner, Seth P.; Loriot, Yohann; Hoffman-Censits, Jean; Valderrama, Begona P.; Andresen, Corina; Schnabel, Marco J.; Cole, Suzanne; Daneshmand, Siamak

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer 醋酸阿比曲酮联合泼尼松在黑人和白人转移性去势抵抗性前列腺癌中的前瞻性试验

CANCER

IF5.1

2021-05-05

OAAI

George, Daniel J.; Halabi, Susan; Heath, Elisabeth I.; Sartor, A. Oliver; Sonpavde, Guru P.; Das, Devika; Bitting, Rhonda L.; Berry, William; Healy, Patrick; Anand, Monika; Winters, Carol; Riggan, Colleen; Kephart, Julie; Wilder, Rhonda; Shobe, Kellie; Rasmussen, Julia; Milowsky, Matthew I.; Fleming, Mark T.; Bearden, James; Goodman, Michael; Zhang, Tian; Harrison, Michael R.; McNamara, Megan; Zhang, Dadong; LaCroix, Bonnie L.; Kittles, Rick A.; Patierno, Brendon M.; Sibley, Alexander B.; Patierno, Steven R.; Owzar, Kouros; Hyslop, Terry; Freedman, Jennifer A.; Armstrong, Andrew J.

Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001)

ANNALS OF ONCOLOGY

IF65.4

2020-09-01

OAAI

Necchi, A.; Siefker-Radtke, A. O.; Loriot, Y.; Park, S. H.; Garcia-Donas, J.; Huddart, R. A.; Burgess, E. F.; Fleming, M. T.; Rezazadeh, A.; Mellado, B.; Varlamov, S.; Joshi, M.; Duran, I.; Zakharia, Y.; Fu, M.; Santiago-Walker, A.; O'Hagan, A.; Monga, M.; Tagawa, S. T.

PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations

ANNALS OF ONCOLOGY

IF65.4

2020-09-01

OAAI

Somford, D. M.; Daneshmand, S.; Grivas, P.; Sridhar, S.; Gupta, S.; Bellmunt, J.; Sonpavde, G.; Fleming, M. T.; Lerner, S. P.; Loriot, Y.; Li, A.; Takkele, H.; Andresen, C.; Rearden, J.; Shepherd, S. Peacock; Schnabel, M. J.; Pal, S. K.

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer

CANCER

IF5.1

2020-08-05

OAAI

Zhang, Tian; Harrison, Michael R.; O'Donnell, Peter H.; Alva, Ajjai S.; Hahn, Noah M.; Appleman, Leonard J.; Cetnar, Jeremy; Burke, John M.; Fleming, Mark T.; Milowsky, Matthew, I; Mortazavi, Amir; Shore, Neal; Sonpavde, Guru P.; Schmidt, Emmett, V; Bitman, Bojena; Munugalavadla, Veerendra; Izumi, Raquel; Patel, Priti; Staats, Janet; Chan, Cliburn; Weinhold, Kent J.; George, Daniel J.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2019-07-25

940

OAAI

Loriot, Y.; Necchi, A.; Park, S. H.; Garcia-Donas, J.; Huddart, R.; Burgess, E.; Fleming, M.; Rezazadeh, A.; Mellado, B.; Varlamov, S.; Joshi, M.; Duran, I.; Tagawa, S. T.; Zakharia, Y.; Zhong, B.; Stuyckens, K.; Santiago-Walker, A.; De Porre, P.; O'Hagan, A.; Avadhani, A.; Siefker-Radtke, A. O.

Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2019-07-01

PREAI

Taplin, Mary-Ellen; Hussain, Arif; Shah, Satish; Shore, Neal D.; Edenfield, William Jeffery; Sartor, Oliver A.; Nordquist, Luke T.; Agrawal, Manish; Clark, William; Wise, David R.; Oh, William K.; Fleming, Mark T.; Butrynski, James E.; Chatta, Gurkamal S.; Bupathi, Manojkumar; Lebedinsky, Claudia; Senderowicz, Adrian; Li, Jian; Colak, Gozde; Nash, David; Trojer, Patrick; Bradley, William D.; Piel, Jessica; Antonarakis, Emmanuel S.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes

EUROPEAN UROLOGY

IF25.2

2018-05-01

PREAI

Galsky, Matthew D.; Wang, Huan; Hahn, Noah M.; Twardowski, Przemyslaw; Pal, Sumanta K.; Albany, Costantine; Fleming, Mark T.; Starodub, Alexander; Hauke, Ralph J.; Yu, Menggang; Zhao, Qianqian; Sonpavde, Guru; Donovan, Michael J.; Patel, Vaibhav G.; Sfakianos, John P.; Domingo-Domenech, Josep; Oh, William K.; Akers, Nicholas; Losic, Bojan; Gnjatic, Sacha; Schadt, Eric E.; Chen, Rong; Kim-Schulze, Seunghee; Bhardwaj, Nina; Uzilov, Andrew V.

Intraoperative Radiation Boost to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report

FRONTIERS IN ONCOLOGY

IF3.3

2018-03-23

OAAI

Thomas, Tarita O.; Small, William Jr Jr; Fleming, Mark; Kang, Song; Hoefer, Richard A.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Atezolizumab在接受铂类化疗后进展的局部晚期和转移性尿路上皮癌患者中的应用: 一项单臂，多中心，2期试验

LANCET

IF88.5

2016-05-01

3.0K

OAAI

Rosenberg, Jonathan E.; Hoffman-Censits, Jean; Powles, Tom; van der Heijden, Michiel S.; Balar, Arjun V.; Necchi, Andrea; Dawson, Nancy; O'Donnell, Peter H.; Balmanoukian, Ani; Loriot, Yohann; Srinivas, Sandy; Retz, Margitta M.; Grivas, Petros; Joseph, Richard W.; Galsky, Matthew D.; Fleming, Mark T.; Petrylak, Daniel P.; Perez-Gracia, Jose Luis; Burris, Howard A.; Castellano, Daniel; Canil, Christina; Bellmunt, Joaquim; Bajorin, Dean; Nickles, Dorothee; Bourgon, Richard; Frampton, Garrett M.; Cui, Na; Mariathasan, Sanjeev; Abidoye, Oyewale; Fine, Gregg D.; Dreicer, Robert

研究方向